Edward Holso

Biography

Ed is the Chief Scientific Officer at KDAc Therapeutics. He is also the director of the medicinal chemistry group in the Stanley Center for Psychiatric Research and a director of chemistry in the Chemical Biology Platform at the Broad Institute. He joined the Stanley Center to design and implement a range of biologic strategies toward developing novel therapies in central nervous system related disorders including schizophrenia, bipolar disorder, and cognitive impairment. Prior to that

Research Interest

Ed worked in medicinal chemistry and pharmaceutical development roles for Infinity Pharmaceuticals and Merck & Co.